Multi-omic data driven drug discovery and indication prioritisation platform in...
Multi-omic data driven drug discovery and indication prioritisation platform in oncology
With 20 % of patients responding to their treatment and 10M dying every year, cancer is a recognised societal challenge. While data-driven approaches can double the clinical trials success rate, the pharma industry lacks tools to...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
TIN2012-31377
ADQUISICION DE CONOCIMIENTO EN FARMACOPROTEOMICA MEDIANTE ME...
39K€
Cerrado
RECeSS
Robust Explainable Controllable Standard for drug Screening
190K€
Cerrado
DevelopMed
Developing the Next Generation of Research Leaders in Precis...
3M€
Cerrado
GenDrug
Genetically anchored drug target discovery for neglected dis...
1M€
Cerrado
RTI2018-101481-B-I00
DESARROLLO DE UNA PLATAFORMA DE MEDICINA DE PRECISION PARA E...
92K€
Cerrado
LifeTime
Revolutionizing Healthcare by Tracking and Understanding Hum...
1M€
Cerrado
Información proyecto mCUBE
Duración del proyecto: 24 meses
Fecha Inicio: 2022-07-29
Fecha Fin: 2024-07-31
Líder del proyecto
EPIGENE LABS SAS
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Descripción del proyecto
With 20 % of patients responding to their treatment and 10M dying every year, cancer is a recognised societal challenge. While data-driven approaches can double the clinical trials success rate, the pharma industry lacks tools to leverage the large amount of data generated in their drug discovery processes.
We are developing mCUBE, an AI-powered platform that scales precision oncology for drug discovery and repurposing. Best-in-class and user-centric platform, mCUBE encapsulates a cancer-agnostic clinical data harmonisation module with an integrative approach to multi-omic data analysis. As our solution increases in value and allows us to move up the value chain, our initial SaaS business model will progressively switch to a drug discovery model. With mCUBE, we will identify and validate new drug candidates to license IP assets to pharma companies. By 2025, we expect to sign a deal of €25M with a biopharma partner. We will disrupt he oncology market for the benefits of cancer patients.